Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05093959
PHASE2

Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction

Sponsor: Wake Forest University Health Sciences

View on ClinicalTrials.gov

Summary

Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects of 20 weeks of 1500 mg/day of metformin on physical function, quality of life (QOL), microbiome diversity, leaky gut, and systemic inflammation in patients with 86 older patients with heart failure with preserved ejection fraction (HFpEF).

Key Details

Gender

All

Age Range

60 Years - Any

Study Type

INTERVENTIONAL

Enrollment

86

Start Date

2022-01-04

Completion Date

2026-04

Last Updated

2026-01-06

Healthy Volunteers

No

Interventions

DRUG

Metformin

An extended release formulation will be used which improves compliance and reduces GI side effects.

DRUG

Placebo

Placebo is a biologically inert substance placed in capsules to match appearance of active intervention

Locations (2)

Atrium Health Sanger Heart and Vascular Clinic Institute

Charlotte, North Carolina, United States

Wake Forest School of Medicine

Winston-Salem, North Carolina, United States